Adaptive Biotechnologies (ADPT) Current Deferred Revenue (2018 - 2026)

Adaptive Biotechnologies has disclosed Current Deferred Revenue across 9 years of filings, most recently posting $53.9 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue fell 28.5% year-over-year to $53.9 million; the TTM figure through Jun 2026 stood at $53.9 million (down 28.5% YoY), while the FY2025 annual figure was $46.2 million, down 44.3% from the prior year.
• Current Deferred Revenue came in at $53.9 million for Q2 2026 at Adaptive Biotechnologies, up from $50.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $168.4 million in Q1 2022 to a low of $42.5 million in Q3 2025.
• Average Current Deferred Revenue over 5 years is $94.2 million, with a median of $91.0 million recorded in 2024.
• Year-over-year, Current Deferred Revenue soared 114.94% in 2022 and plunged 49.73% in 2025.
• Over 5 years, Current Deferred Revenue stood at $122.7 million in 2022, then fell by 23.87% to $93.4 million in 2023, then dropped by 11.22% to $82.9 million in 2024, then slumped by 44.3% to $46.2 million in 2025, then increased by 16.59% to $53.9 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $53.9 million in Q2 2026, $50.2 million in Q1 2026, and $46.2 million in Q4 2025.